Nebraska Hematology/Oncology, PC

Lincoln, Nebraska 68510-2482

1 studies enrolling now · 25 studies all time

What they study most

Advanced Breast Cancer, Advanced Multiple Myeloma, Advanced Prostate Cancer, Breast Cancer, Carcinoma, Transitional Cell, Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia (CLL), Chronic Myelogenous Leukemia - Chronic Phase, DLBCL Transformed From Indolent Lymphoma, Diffuse Large B-cell Lymphoma, Follicular Grade 3 Lymphoma, Lung Cancer

Studies at this site

• Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib — Recruiting now
• Connect® MM- The Multiple Myeloma Disease Registry — Stopped early
• A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer — Stopped early
• Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1) — Running, not enrolling
• A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer — Running, not enrolling
• Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer — Completed
• Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia — Running, not enrolling
• Palbociclib in Real World Practice — Completed
• Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer — Completed
• Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC — Completed
• informCLL™: A Disease Registry for Patients With Chronic Lymphocytic Leukemia — Completed
• Study in Patients With Unresectable And Metastatic Melanoma: The Optimize Study — Completed
• Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant — Completed
• Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia — Stopped early
• A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM) — Completed
• Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry — Completed
• A Study to Evaluate the Efficacy of Lenalidomide as Maintenance Therapy After Completion of First-line Combination Chemotherapy in Patients With Mantle Cell Lymphoma (MCL). — Stopped early
• A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer — Completed
• Phase 2b Study of Taxol Plus Sorafenib or Placebo in Patients With Advanced Breast Cancer — Status unconfirmed
• Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer — Completed
• Study of Bavituximab Plus Docetaxel in Patients With Locally Advanced or Metastatic Non-Squamous Non Small-Cell Lung Cancer — Completed
• Continued Efficacy and Safety of Zoledronic Acid (q 4 Wks vs. q 12 Wks) in the 2nd Year of Treatment in Patients With Bone Metastases From Breast Cancer — Completed
• Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma — Completed
• Expanded Access Study of Satraplatin Plus Prednisone in Patients With Hormone Refractory Prostate Cancer (HRPC) — Stopped early
• DN-101 in Combination With Docetaxel in Androgen-Independent Prostate Cancer (AIPC) (AIPC Study of Calcitriol Enhancing Taxotere [ASCENT-2]) — Stopped early